Study reveals approximately 60 per cent cancer patients do not respond effectively to chemotherapy treatments – health


Almost 60 per cent of all cancer patients do not respond effectively to chemotherapy treatments, as estimated by scientists from Purdue University. In recent research, they say that the results can also be even worse – as many of those same patients experience poisonous and from time to time lethal side effects.

Now, a Purdue University scientist and entrepreneur working to use simple LED light to help decide whether sure chemotherapy options will work for particular patients. The work is published in Scientific Reports.”We are the usage of a mastery similar to Doppler radar used in the weather to advance personalized medicine,” said David Nolte, the Edward M. Purcell Distinguished Professor of Physics and Astronomy in Purdue’s College of Science. “We take the LED light and shine it on biopsies. We then apply chemotherapy to the biopsies and analyse how the light scatters off the tissues.”

Nolte, who also is a member of the Purdue University Centre for Cancer Research, said the light scattering dynamics give scientists and doctors detailed information approximately the likelihood of a chemotherapy drug being effective for a patient. Nolte said they have got results inside 24 hours. This first trial looked at biodynamic imaging on human patients with ovarian cancer.

“We look for signs of apoptosis, or what we call the controlled death of cells,” Nolte said. “Apoptosis is the sign that indicates the effectiveness of the chemotherapy for this patient’s tissues and tumours. For some cancers, there are such a large amount of remedy options to be had that it’s like a doctor is attempting to fit square pegs in circular holes until the desired outcome is found. We need to make this process better for patients.”

Nolte has worked with several groups inside the Purdue entrepreneurial and commercialization ecosystem, including the Purdue Foundry, on commerce plan development and management searches. AniDyn, a medical technology startup, was once spun out of Purdue by professors Nolte and John J. Turek. AniDyn is focused on the development and commercialization of live-tissue imaging platform technologies.

Nolte also works closely with the Purdue Research Foundation Office of Technology Commercialisation to patent and license his technologies.

(This story has been published from a wire agency feed without modifications to the text.)

Follow more stories on Facebook and Twitter

Top stories / News


Please enter your comment!
Please enter your name here